Investment Rating - The report suggests a positive investment outlook for the medical device sector, particularly in brain-computer interface devices, which are expected to see accelerated commercialization due to supportive policies [1][3]. Core Insights - Recent policies have significantly increased support for innovation in medical devices, with the National Medical Products Administration actively promoting faster market entry for brain-computer interface devices, indicating a diverse application landscape and substantial future potential [1][3]. - The pharmaceutical sector is witnessing positive developments, such as GSK's approval of mepolizumab for a new indication in COPD patients, marking it as the first monthly administered biologic in China, which is expected to reduce the annual incidence of severe exacerbations significantly [1][32]. - The report highlights the approval of Wegovy® tablets in the U.S. for weight management, emphasizing its potential impact on the market as the first oral GLP-1 receptor agonist for this purpose [37][40]. Summary by Sections Pharmaceutical Sector - Mepolizumab has been approved for COPD treatment in China, with a monthly dosing schedule, targeting a significant patient population [1][32]. - The A/H share innovation drug sector maintains high activity levels, with new drug approvals and cross-border transactions remaining robust [16][28]. Biologics - Wegovy® tablets have been approved in the U.S. for weight management, showing similar weight loss efficacy to its injectable counterpart, with a significant portion of participants achieving substantial weight loss [37][40]. CXO and Pharmaceutical Supply Chain - The CXO sector continues to show upward momentum, supported by a stable order backlog, with November financing levels slightly above the annual average [44][46]. Medical Devices - The centralized procurement process for high-value medical consumables is progressing steadily, with high selection rates in multiple rounds of bidding, indicating a favorable environment for leading domestic companies [2][52]. Retail Pharmacy - The industry is undergoing a consolidation phase, with leading companies expected to benefit from increased market share through mergers and acquisitions [2][3]. Medical Services and Consumer Healthcare - Aier Eye Hospital's acquisition of 39 institutions for 960 million yuan strengthens its market position, with the acquired entities showing signs of financial recovery [2][3].

Investment Rating - The report suggests a focus on companies such as BYD, Geely Automobile, and others in the automotive sector, as well as companies like Li Auto-W, Xpeng Motors-W, and others in the smart technology and robotics sectors [2]. Core Insights - The Central Economic Work Conference has outlined six key tasks related to the automotive industry, emphasizing domestic demand, innovation, reform, openness, coordinated development, and green transformation, which are expected to stabilize and boost automotive demand [12][13]. - The report highlights that passenger car exports have maintained a year-on-year growth rate of over 20% for six consecutive months, with expectations for double-digit growth in wholesale exports by 2026 due to recovering demand in markets like Russia and the increasing export of new energy vehicles [14]. - The report notes that the smart driving experience is expected to improve significantly with advancements in new architectures and high-performance chips, leading to increased consumer acceptance and sales for leading companies in smart driving technology [17][20]. Industry Data Tracking Market and Sector Performance - The Shanghai and Shenzhen 300 Index increased by 1.95%, while the Shenwan Automotive Index rose by 2.74% [21]. - The top five stocks with the highest gains this week included Chaojie Co. (+41.6%), Longji Machinery (+33.7%), and others, while the top five stocks with the largest declines included Meidong Automotive (-6.5%) and others [28]. Passenger Car Sales Data - In December 2025, the wholesale sales of passenger cars reached 568,000 units, a year-on-year decrease of 9%, while the retail sales were 536,000 units, also down 11% year-on-year [4][32]. - For November 2025, wholesale sales were 2.991 million units, a year-on-year increase of 1.7%, with new energy vehicle wholesale sales at 1.694 million units, up 17.6% year-on-year [5][35]. - The report indicates that the export of passenger cars in November was 594,000 units, reflecting a 50% year-on-year increase, with new energy vehicle exports reaching 273,000 units, up 244.1% year-on-year [51][57]. Industry Dynamics - The report discusses the rapid development of smart technology and robotics, with significant advancements in autonomous driving and AI integration in vehicles, indicating a shift towards a more intelligent automotive market [17][19]. - The report also mentions the increasing focus on new energy vehicles and the expansion of charging infrastructure, which has reached 19.322 million charging points, marking a 52% year-on-year growth [73].

本周行情综述 风险提示 地缘政治扰动超预期；海外经济出现衰退；行业及国际政策环境变化。 敬请参阅最后一页特别声明 1 原油：本周油价上涨后回落。白宫下令美军在未来至少两个月内专注于对委内瑞拉石油的"封锁"，当前美国更 倾向于使用经济手段，而非军事手段向委内瑞拉施压。此外，海湾地区裂痕加深，沙特对也门发动空袭，中东局 势存升级风险。地缘因素推升油价。本周五，因泽连斯基将于周日与特朗普讨论领土问题，市场预期和平协议或 进一步推进，叠加供应过剩担忧加剧，油价快速回落。整体看，当前油价仍围绕地缘与供需博弈。截止 12 月 26 日，WTI 现货收于 56.74 美元，环比+0.59 美元；BRENT 现货收于 63.73 美元。EIA12 月 12 日当周商业原油库存 环比-127.4 万桶，前值-181.2 万桶。其中库欣原油环比-74.2 万桶，前值+30.8 万桶。汽油库存环比+480.8 万 桶，前值+639.7 万桶。炼厂开工率环比+0.3%至 94.8%。美国原油库存下降，净进口量环比减少。美国产量 1384.3 万桶/天，美国净进口数据环比-27.9%。截至 12 月 23 日当周，美国活跃石油钻机数环 ...

Investment Rating - The report does not explicitly state an investment rating for the industry. Core Insights - The dexterous hand is a high-degree-of-freedom robotic end effector that mimics human hand functionality, providing flexibility and adaptability that surpass traditional mechanical grippers. It is a critical component of humanoid robots, accounting for approximately 20%-30% of the total cost of the robot. The future value of humanoid robots will largely depend on the dexterous hand's flexibility and collaborative capabilities [4][5]. Summary by Sections 1. Key Technologies and Comparison of Dexterous Hands - The design of dexterous hands is inspired by the complex structure and functionality of human hands, enabling robots to perform diverse tasks such as grasping and manipulation. A typical dexterous hand system consists of four key components: drive system, transmission system, sensor system, and control system [13][14]. - The trend in dexterous hand technology is towards electric drive systems combined with composite transmission and tactile sensing [14][22]. 2. Drive Devices: Domestic Competitive Advantages - Electric motor drives are the mainstream technology due to their precision and cost-effectiveness. The report highlights that the demand for motors will increase with the rise in degrees of freedom in dexterous hands, presenting market opportunities for suppliers of hollow cup motors and brushless gear motors [5][22]. 3. Transmission Methods: Ball Screw Advantages - The report indicates that ball screw transmission is becoming a dominant trend in dexterous hand design due to its high load-bearing capacity and precision, making it suitable for industrial applications [35][41]. 4. Sensors: Increasing Sensor Count - The report notes that the number of sensors in dexterous hands is on the rise, with various types including tactile, force, and position sensors being utilized to enhance interaction with external objects [47][52]. 5. Dexterous Hands and Related Industry Chain - The dexterous hand represents a high-value component with significant barriers to entry, indicating a robust market potential for companies involved in its development and production [5][44].

家电行业周报 202 51 22 7 2025 年 12 月 27 日 买入（维持评级） 行业周报 证券研究报告 国金证券研究所 分析师：赵中平（执业 S1130524050003 ） zhaozhongping ＠gjzq.com.cn 分析师：王刚（执业 S1130524080001 ）分析师：蔡润泽（执业 S1130525090001 ） wang_g ＠gjzq.com.cn cairunze ＠gjzq.com.cn 错期影响下空调 1 月排产反弹，冰冷新兴地区贡献增长 错期影响下空调 1 月排产反弹，冰冷新兴地区贡献增长 空调排产：错期影响下 1 月数据亮眼，但终端需求预计仍然偏弱。2026 年 1 月家用空调内销排产 786 万台，同比+8.9%； 出口排产 1065 万台，同比+1.2%。这一反弹主要原因为 2026 年春节落于 2 月，企业将部分 2 月产能前移至 1 月，以 应对节前交付及促销需求，属于排产节奏的短期调整，但终端需求预计仍然偏弱。出口端虽暂时转正，但欧美市场旺 季已过且库存高企，新订单增速受限，叠加海外工厂产能替代效应增强，中国成品出口的长期增长仍面临结构性压力。 冰箱排产 ...

Investment Rating - The report suggests a positive outlook for the pharmacy and traditional Chinese medicine sectors, anticipating a recovery in 2026 after a weak performance in 2025 [2][5]. Core Insights - The pharmacy sector is expected to benefit from market consolidation, with leading companies likely to increase their market share through mergers and acquisitions during the industry clearing phase [3][11]. - The traditional Chinese medicine sector is projected to stabilize and potentially recover, driven by an increase in flu incidence and the upcoming update of the essential drug list [57][60]. Summary by Sections Pharmacy Sector - **Market Review**: The pharmacy sector faced significant challenges in 2025, with a decline in same-store sales and an overall reduction in the number of operating stores since Q4 2024 [5][20]. - **Policy Environment**: Regulatory measures are promoting a more compliant and healthier industry ecosystem, which is expected to benefit leading companies [14][15]. - **Market Size**: In the first ten months of 2025, the sales scale of physical pharmacies was 501.3 billion yuan, a year-on-year decrease of 1.6%, primarily due to a decline in non-pharmaceutical sales [16][21]. - **Competitive Landscape**: The number of pharmacies in China reached approximately 684,000 by the end of 2024, with a notable increase in store closures, particularly among smaller chains [20][24]. - **Marginal Performance**: There has been a slight recovery in retail sales data, with leading companies showing improved performance through cost reduction and efficiency measures [32][34]. - **Outlook for 2026**: Focus on market consolidation and the development of non-pharmaceutical products is recommended, as leading companies are expected to enhance their market share [44][52]. Traditional Chinese Medicine Sector - **Market Review**: The traditional Chinese medicine sector experienced overall weak performance in 2025, with some companies seeing temporary valuation increases due to innovative pipelines [57][58]. - **In-Hospital Opportunities**: The upcoming update of the essential drug list is expected to benefit companies with products that have the potential to be included [60]. - **Out-of-Hospital Opportunities**: An increase in flu incidence in Q4 2025 is anticipated to aid in inventory digestion, with some companies expected to see improved performance [60]. - **High Dividend Stocks**: Companies such as Lingrui Pharmaceutical, Jichuan Pharmaceutical, and Dong'e Ejiao are highlighted as stable high-dividend investment opportunities [60].

Investment Rating - The report suggests a positive outlook for the high-end equipment manufacturing industry in China, emphasizing a "dual-driven" growth model characterized by strong domestic demand and robust international expansion [3][5]. Core Insights - The high-end equipment industry in China is experiencing a structural transformation, with a focus on technological advancements and brand development, leading to increased global market share [3]. - The report highlights two main investment themes: the technological self-reliance driven by AI and the deepening international expansion of Chinese equipment manufacturers [4][5]. - Key sectors to watch include gas turbines, industrial mother machines, controlled nuclear fusion, quantum computing, robotics, and 3D printing, which are expected to drive future growth [4][41]. Summary by Sections Domestic Manufacturing and Investment - Manufacturing investment in China is under short-term pressure, but high-end manufacturing and equipment sectors are emerging as growth engines, with a 1.9% year-on-year increase in manufacturing fixed asset investment [15][19]. - The report notes that high-tech manufacturing and equipment manufacturing sectors maintain high levels of activity despite overall investment slowdowns [15][22]. Export Performance - China's high-end equipment exports are performing well, driven by the global AI investment boom and recovery in demand from developed markets [28][31]. - In the first ten months of 2025, China's exports of electromechanical products reached 13.43 trillion yuan, marking an 8.7% year-on-year increase [28][31]. Technological Self-Reliance - The report emphasizes the importance of technological self-reliance, particularly in sectors like gas turbines and quantum computing, which are expected to see significant growth due to increasing global demand [4][48]. - The global gas turbine market is projected to grow significantly, with sales expected to rise from 44.1 GW in 2023 to an average of 60 GW from 2024 to 2026, reflecting a 36% increase [49][50]. International Expansion - Chinese equipment manufacturers are poised for further international growth, particularly in emerging markets, with sectors like engineering machinery and agricultural equipment expected to see substantial export growth [5][41]. - The report highlights the potential for Chinese companies in the oil and gas equipment sector, particularly in the Middle East, where demand is expected to rise significantly [5][13].

2024 年起的监管政策压缩了高频 T0 策略的 Alpha 空间，倒逼管理人从高频博弈转向中低频基本面因子挖掘，2025 年产品平均换手率普遍下降。叠加指数成分股质量提升，量化指增也从短期交易工具，升级为具备长期资产配置价 值的产品，完成从规模扩张到策略与价值逻辑的双重重塑。 基金管理人与量化指增策略体系介绍 qqqqqqqqqqqqqqqqqqq 量化指增产品市场分析 近年量化指增是权益市场的核心热门赛道，其市场规模从 2020 年的 958.50 亿元快速扩张至 2025 年的超 2500 亿元， 同时呈现"头部集中、平均规模抬升"的结构特征，头部产品规模不断向上突破。 永赢基金管理有限公司是宁波银行与新加坡华侨银行旗下机构合资设立的中外资基金公司，截至 2025 年三季度，其 管理规模超 6200 亿元。以固收类产品为核心，占比超 78%，股混型产品规模稳步增长，业务布局多元且稳健。 其量化指增产品体系分为三类：常规宽基指增（跟踪沪深 300 等指数，以"核心+卫星"策略融合多因子与基本面方 法，挖掘持续超额收益）、特殊基准指增（针对中证 A500、科创 100 等定制增强，匹配指数风格并严控风险）、 ...

Investment Rating - The report suggests that the domestic HNB (Heated Not Burned) industry is on the verge of significant growth, driven by international tobacco giants shifting towards new tobacco products [5]. Core Insights - The global cigarette market is experiencing an irreversible decline, with smoking rates dropping from 30.75% in 2005 to 21.74% in 2022, and cigarette market size decreasing from 53,908 billion sticks in 2018 to an estimated 51,561 billion sticks in 2024, reflecting a CAGR of -0.74% [1][13]. - Major tobacco companies, including Philip Morris International (PMI), are focusing on new tobacco products as a core growth driver, with PMI planning for over two-thirds of its revenue to come from new tobacco products by 2030 [1][20]. - The Japanese market serves as a reference point, showing that the rapid penetration of heated tobacco products has not negatively impacted tax revenues, with the market size growing from 37.28 billion sticks in 2019 to 64.50 billion sticks in 2024, a CAGR of 11.59% [2][51]. Summary by Sections Section 1: HNB as a Core Development Category - International tobacco giants are increasingly focusing on new tobacco products as a long-term performance core, with significant contributions to profitability [1.1]. - The global market for heated tobacco and electronic cigarettes is projected to grow, with sales expected to reach $38.85 billion and $23.04 billion respectively by 2024, reflecting growth rates of 12.7% and 9.5% [1.1][13]. Section 2: Domestic Tobacco Industry Challenges - The traditional cigarette market in China is under pressure, with production increasing from 23,642 billion sticks in 2019 to 24,655 billion sticks in 2024, but at a slowing growth rate [3][55]. - The inventory levels in the tobacco industry have risen significantly, from 150 billion yuan in 2010 to approximately 4,394 billion yuan in 2024, indicating a high stock level [3][56]. Section 3: Regulatory Framework for HNB - The regulatory landscape for heated tobacco products is becoming clearer globally, with established frameworks in the US, Japan, and Europe, providing a roadmap for compliance [4][62]. - The US has implemented a structured regulatory process for HNB products, which includes pre-market tobacco application (PMTA) requirements, ensuring a predictable compliance environment [4][66]. Section 4: Domestic Product Development and Market Readiness - Chinese tobacco companies have made significant strides in developing HNB products, with several companies launching domestic HNB devices and achieving a substantial number of patents in the field [4][5]. - The report emphasizes the importance of product innovation and international expansion for the high-quality development of the domestic tobacco industry [3][5]. Section 5: Company Analysis - Companies like Huabao International and Smoore International are highlighted for their strong technical reserves and potential for growth in the HNB sector, with Huabao expected to benefit from its leading position in the flavoring segment [5][5.1][5.2].

摘要 根据 Wind 数据，折价成交个券中，"24 诚通控股 MTN010B"债券估值价格偏离幅度较大。净价上涨成交个券中，"京 资 K10"估值价格偏离程度靠前。净价上涨成交二永债中，"25 平安银行永续债 01BC"估值价格偏离幅度较大；净价 上涨成交商金债中，"25 张家港农商科创债 01"估值价格偏离幅度靠前。成交收益率高于 5%的个券中，交运债排名靠 前。 信用债估值收益变动主要分布在[-5,5]区间。非金信用债成交期限主要分布在 2 至 3 年，其中 0.5 年内品种折价成交 占比最高；二永债成交期限主要分布在 4 至 5 年，其中 1 至 3 年品种折价成交占比最高。分行业看，轻工制造行业的 债券平均估值价格偏离最大。 风险提示 统计数据偏差或遗漏，高估值个券出现信用风险 敬请参阅最后一页特别声明 1 扫码获取更多服务 固定收益动态(动态) 图表1：折价成交跟踪 | | | | | 大幅折价个券成交跟踪 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 剩余期限 | 估值价格 ...